Schering-Plough may have lost billions of dollars in the fourth quarter from an acquisition, but its stock jumped Tuesday as the drugmaker's earnings without charges beat expectations.
Schering-Plough's stock almost crawled out of its hole Wednesday after a two-day lashing sparked by the results of a cholesterol drug trial, but the shares fell just before the market's close.
A study suggests the cholesterol drug Vytorin may not help arteries more than a generic. CNN's Dr. Sanjay Gupta reports.
A team of doctors in India successful removed a 2-year-old girl's extra limbs. CNN's Dr. Sanjay Gupta explains.
Led by the emergency contraceptive Plan B, a new class of drugs called "behind-the-counter" is entering the FDA's spotlight.
Big Pharma stocks trounced Big Biotech this year, as Merck and other drugmakers recovered from their woes, and Genentech slid after a couple of very good years.